

Press Release

Lonza Launches Next Generation Vegetarian DHA

Basel, Switzerland, 11 April 2012 –Today Lonza announced the launch of the next generation of vegetarian DHA (DHAid™) products. Based on an overall optimized fermentation process and improved productivity of the proprietary algal strain, the new qualities offer advantages in stability and taste. The product line now includes the new oil products DHAid™ FNO-350 and DHAid™ CL-400 as well as the powdered product DHAid™ Dry.

DHAid™ FNO-350 is a functional nutrition oil containing 350mg DHA per gram and is formulated for various food applications. DHAid™ CL-400 is a clear oil with 400mg DHA per gram, formulated especially for use in dietary supplements. Both oil products are standardized with oleic sunflower oil and allow for a more precise calculation of the final DHA concentration in finished products. DHAid™ Dry is a dry powder formulation for applications in dry blends like special nutrition beverages. All DHAid™ products are produced without use of any solvents. Due to a controlled fermentation process, contaminants often discussed for marine sources of DHA, such as dioxins and heavy metals, can be avoided.

DHA is a type of omega-3 fatty acid that is used by our body as a building block for cell membranes and thus plays an important role in membrane fluidity, flexibility and permeability. Health benefits of DHAid™ include the support of brain development and function as well as heart and eye health. Products displaying the DHAid™ quality seal on the packaging show the consumer that they contain vegetarian DHA from Lonza Ltd, Switzerland.

To learn more about DHAid™ please visit www.dhaid.info.

About Lonza

Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries. Products and services span its customers' needs from research to final product manufacture. It is the global leader in the production and support of active pharmaceutical ingredients both chemically as well as biotechnologically. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products. Lonza is also the world leader in microbial control providing innovative, chemistry-based and related solutions to destroy or to selectively inhibit the growth of harmful microorganisms. Its activities encompass the areas of water treatment, personal care, health and hygiene, industrial preservation, materials protection, and wood treatment. In addition, Lonza is a leader in cell-based research, endotoxin detection and cell therapy manufacturing. Furthermore, the company is a leading provider of value chemical and biotech ingredients to the nutrition and agro markets.

Press Release

Lonza is headquartered in Basel, Switzerland and is listed on the SIX Swiss Exchange and secondary listed on the Singapore Exchange Securities Trading Limited ("SGX-ST"). Lonza is not subject to the SGX-ST's continuing listing requirements. Lonza is subject to the listing rules of the SIX Swiss Exchange, which do not have specific requirements equivalent to the listing rules of the SGX-ST in respect of interested person transactions, acquisition and realizations, and delisting. In 2011, the company had sales of CHF 2.692 billion. Further information can be found at www.lonza.com.

Further Information

Lonza Group Ltd
Head of Corporate Communications
Dominik Werner
Tel +41 61 316 8798
Fax +41 61 316 9798
dominik.werner@lonza.com

Lonza Group Ltd
Investor Relations
Dirk Oehlers
Tel +41 61 316 8540
Fax +41 61 316 9540
dirk.oehlers@lonza.com

Lonza Group Ltd
Media Relations
Melanie Disa
Tel +1 201 316 9413
Fax +1 201 696 3533
melanie.disa@lonza.com